Login to Your Account



Other News To Note


Friday, March 25, 2011
AltheRx Inc., of Chadds Ford, Pa., purchased from GlaxoSmithKline plc, of London, Solabegron, a beta3-adrenoceptor agonist that has demonstrated positive results in Phase II programs for the treatment of overactive bladder in women and irritable bowel syndrome. The company said it plans to advance the overactive bladder program for Solabegron into Phase III this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription